Full Text:   <1378>

CLC number: R969.1

On-line Access: 2010-01-06

Received: 2010-03-10

Revision Accepted: 2010-08-29

Crosschecked: 2010-12-12

Cited: 3

Clicked: 3465

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2011 Vol.12 No.1 P.32-39

http://doi.org/10.1631/jzus.B1000085


A multiple-dose pharmacokinetics of polyethylene glycol recombinant human interleukin-6 (PEG-rhIL-6) in rats


Author(s):  Xue-ling He, Hai-lin Yin, Jiang Wu, Ke Zhang, Yan Liu, Tao Yuan, Hai-lin Rao, Liang Li, Guang Yang, Xue-mei Zhang

Affiliation(s):  Institute of Biomedical Engineering, West China Center of Medical Sciences, Sichuan University, Chengdu 610041, China, Laboratory Animal Center of Sichuan University, Chengdu 610041, China, Chengdu Institute of Biological Products, China National Biotic Group (CNBG), Chengdu 610023, China

Corresponding email(s):   hxlscu@163.com, xmzhang@tom.com

Key Words:  Polyethylene glycol, Recombinant human interleukin-6, Pharmacokinetics, Rat


Xue-ling He, Hai-lin Yin, Jiang Wu, Ke Zhang, Yan Liu, Tao Yuan, Hai-lin Rao, Liang Li, Guang Yang, Xue-mei Zhang. A multiple-dose pharmacokinetics of polyethylene glycol recombinant human interleukin-6 (PEG-rhIL-6) in rats[J]. Journal of Zhejiang University Science B, 2011, 12(1): 32-39.

@article{title="A multiple-dose pharmacokinetics of polyethylene glycol recombinant human interleukin-6 (PEG-rhIL-6) in rats",
author="Xue-ling He, Hai-lin Yin, Jiang Wu, Ke Zhang, Yan Liu, Tao Yuan, Hai-lin Rao, Liang Li, Guang Yang, Xue-mei Zhang",
journal="Journal of Zhejiang University Science B",
volume="12",
number="1",
pages="32-39",
year="2011",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1000085"
}

%0 Journal Article
%T A multiple-dose pharmacokinetics of polyethylene glycol recombinant human interleukin-6 (PEG-rhIL-6) in rats
%A Xue-ling He
%A Hai-lin Yin
%A Jiang Wu
%A Ke Zhang
%A Yan Liu
%A Tao Yuan
%A Hai-lin Rao
%A Liang Li
%A Guang Yang
%A Xue-mei Zhang
%J Journal of Zhejiang University SCIENCE B
%V 12
%N 1
%P 32-39
%@ 1673-1581
%D 2011
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1000085

TY - JOUR
T1 - A multiple-dose pharmacokinetics of polyethylene glycol recombinant human interleukin-6 (PEG-rhIL-6) in rats
A1 - Xue-ling He
A1 - Hai-lin Yin
A1 - Jiang Wu
A1 - Ke Zhang
A1 - Yan Liu
A1 - Tao Yuan
A1 - Hai-lin Rao
A1 - Liang Li
A1 - Guang Yang
A1 - Xue-mei Zhang
J0 - Journal of Zhejiang University Science B
VL - 12
IS - 1
SP - 32
EP - 39
%@ 1673-1581
Y1 - 2011
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1000085


Abstract: 
Radiation therapy has been widely applied in cancer treatment. However, it often causes thrombocytopenia (deficiency of white blood cells) as an adverse effect. recombinant human interleukin-6 (rhIL-6) has been found to be a very effective way against this thrombocytopenia, but IL-6 has low stability in blood, which reduces its efficacy. To increases the stability and half-life of rhIL-6, it was modified by polyethylene glycol (PEG). The pharmacokinetics and the tissue distribution of PEG-rhIL-6 labeled with 125I were examined after subcutaneous injection in rats. The pharmacokinetic pattern of PEG-rhIL-6 was defined with linear-kinetics, and we fitted a one-compartment model with half-lives of 10.44–11.37 h (absorption, t1/2Ka) and 19.77–21.53 h (elimination, t1/2Ke), and peak concentrations at 20.51–21.96 h (tpeak) in rats. Half-lives and tpeak of PEG-rhIL-6 were longer than those of rhIL-6 previously reported. In the present study, for deposition of PEG-rhIL-6 in rats, the tissue distribution examination showed that blood was the major organ involved, rather than liver. However, as to the elimination of PEG-rhIL-6, the major organ was the kidney. The excretion fraction of the injection dose recovered from urine was 23.32% at 192 h after subcutaneous administration. Less than 6% of PEG-rhIL-6 was eliminated via the feces at 192 h. These results indicate that PEG-rhIL-6 is a good candidate drug formulation for patients with cancer.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Bailon, P., Palleroni, A., Schaffer, C.A., Spence, C.L., Fung, W.J., Porter, J.E., Ehrlich, G.K., Pan, W., Xu, Z.X., Modi, M.W., et al., 2001. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug. Chem., 12(2):195-202.

[2]Banks, R.E., Forbes, M.A., Patel, P.M., Storr, M., Hallam, S., Clarke, D., Novick, D., Ingham, E., Bowmer, C., Southgate, J., et al., 2000. Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects. Cytokine, 12(4):388-396.

[3]Bracho, F., Krailo, M.D., Shen, V., Bergeron, S., Davenport, V., Liu-Mares, W., Blazar, B.R., Panoskaltsis-Mortari, A., van de Ven, C., Secola, R., et al., 2001. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/ refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities. Clin. Cancer Res., 7(1):58-67.

[4]Caliceti, P., Veronese, F.M., 2003. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev., 55(10):1261-1277.

[5]Castell, J.V., Geiger, T., Gross, V., Andus, T., Walter, E., Hirano, T., Kishimoto, T., Heinrich, P.C., 1988. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur. J. Biochem., 177(2):357-361.

[6]Castell, J.V., Klapprot, J., Gross, V., Walter, E., Andus, T., Snyers, L., Content, J., Heinrich, P.C., 1990. Fate of interleukin-6 in the rat. Eur. J. Biochem., 189(1):113-118.

[7]Cindric, M., Cepo, T., Galic, N., Bukvic-Krajacic, M., Tomczyk, N., Vissers, J.P., Bindila, L., Peter-Katalinic, J., 2007. Structural characterization of PEGylated rHuG-CSF and location of PEG attachment sites. J. Pharm. Biomed. Anal., 44(2):388-395.

[8]Dosio, F., Arpicco, S., Brusa, P., Stella, B., Cattel, L., 2001. Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics. J. Control Release, 76(1-2):107-117.

[9]Drayer, A.L., Sibinga, C.T., Blom, N.R., de Wolf, J.T., Vellenga, E., 2000. The in vitro effects of cytokines on expansion and migration of megakaryocyte progenitors. Br. J. Haematol., 109(4):776-784.

[10]Hinds, K.D., Kim, S.W., 2002. Effects of PEG conjugation on insulin properties. Adv. Drug Deliv. Rev., 54(4):505-530.

[11]Hu, Z.P., Niu, H.S., Yang, X.X., Li, H.F., Sang, G.W., Li, B., 2006. Recombinant human parathyroid hormone 1–34: pharmacokinetics, tissue distribution and excretion in rats. Int. J. Pharm., 317:144-154.

[12]Kashiwakura, I., Inanami, O., Abe, Y., Takahashi, T.A., Kuwabara, M., 2005. Different radiosensitive megakaryocytic progenitor cells exist in steady-state human peripheral blood. Radiat. Res., 164(1):10-16.

[13]Kishimoto, T., 2003. Interleukin-6 (IL-6). In: Thomson, A.W., Lotze, M.T. (Eds.), The Cytokine Handbook, 4th Ed. Vol. 1, Academic Press, New York, p.281-304.

[14]Kishimoto, T., 2005. Interleukin-6: from basic science to medicine-40 years in immunology. Annu. Rev. Immunol., 23(1):1-21.

[15]Kishimoto, T., 2010. IL-6: from its discovery to clinical applications. Int. Immunol., 22(5):347-352.

[16]Kodera, Y., Tanaka, H., Matsushima, A., Inada, Y., 1992. Chemical modification of l-asparaginase with a comb-shaped copolymer of polyethylene glycol derivative and maleic anhydride. Biochem. Biophys. Res. Commun., 184(1):144-148.

[17]Kozlowski, A., Charles, S.A., Harris, J.M., 2001. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs, 15(7):419-429.

[18]Levy, Y., Hershfield, M.S., Fernandez-Mejia, C., Polmar, S.H., Scudiery, D., Berger, M., Sorensen, R.U., 1988. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. J. Pediatr., 113(2):312-317.

[19]Markwell, M.A., 1982. A new solid-state reagent to iodinate proteins. Anal. Biochem., 125(2):427-432.

[20]Mehvar, R., 2000. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. Pharm. Pharmaceut. Sci., 3(1):125-136.

[21]Nakanishi, H., Yoshioka, K., Joyama, S., Araki, N., Myoui, A., Ishiguro, S., Ueda, T., Yoshikawa, H., Itoh, K., 2004. Interleukin-6/soluble interleukin-6 receptor signaling attenuates proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell line. Am. J. Pathol., 165(2):471-480.

[22]Nojima, Y., Suzuki, Y., Iguchi, K., Shiga, T., Iwata, A., Fujimoto, T., Yoshida, K., Shimizu, H., Takeuchi, T., Sato, A., 2008. Development of poly(ethylene glycol) conjugated lactoferrin for oral administration. Bioconjug. Chem., 19(11):2253-2259.

[23]Parveen, S., Sahoo, S.K., 2006. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Clin. Pharmacokinet., 45(10):965-988.

[24]Pradhananga, S., Wilkinson, I., Ross, R.J., 2002. Pegvisomant: structure and function. J. Mol. Endocrinol., 29(1):11-14.

[25]Rawat, S., Suri, C.R., Sahoo, D.K., 2010. Molecular mechanism of polyethylene glycol mediated stabilization of protein. Biochem. Biophys. Res. Commun., 392(4):561-566.

[26]Ryffel, B., Car, B.D., Woerly, G., Weber, M., DiPadova, F., Kammuller, M., Klug, S., Neubert, R., Neubert, D., 1994. Long-term interleukin-6 administration stimulates sustained thrombopoiesis and acute-phase protein synthesis in a small primate—the marmoset. Blood, 83(8):2093-2102.

[27]Shibata, H., Nakagawa, S., Tsutsumi, Y., 2005. Optimization of protein therapies by polymer-conjugation as an effective DDS. Molecules, 10(1):162-180.

[28]Tsunoda, S., Ishikawa, T., Watanabe, M., Kamada, H., Yamamoto, Y., Tsutsumi, Y., Hirano, T., Mayumi, T., 2001. Selective enhancement of thrombopoietic activity of PEGylated interleukin 6 by a simple procedure using a reversible amino-protective reagent. Br. J. Haematol., 112(1):181-188.

[29]Wang, Y.S., Youngster, S., Grace, M., Bausch, J., Bordens, R., Wyss, D.F., 2002. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv. Drug Deliv. Rev., 54(4):547-570.

[30]Yin, H.L., He, X.L., Xu, B., Liu, X., Yang, G., 2005. The impedance effects of the interleukin-6 on hematopoietic damnification of cyclophosphamide-induced dogs. J. Biomed. Eng., 22(4):798-801 (in Chinese).

[31]Zeuzem, S., Welsch, C., Herrmann, E., 2003. Pharmacokinetics of peginterferons. Semin. Liver Dis., 23(Supp1. 1):23-28.

[32]Zha, J.Q., Zheng, Q.X., Li, Y.L., 1995. Pharmacokinetics of interleukin-6 in mouse. Guangdong Pharm., 5(3):53-54 (in Chinese).

[33]Zhang, Y.J., Xu, Y.J., Zhu, R., Hu, M.J., Li, J.X., Chen, Y.J., Wang, D.J., Fan, W., 2007. Pharmacokinetics, tissue distribution and excretion of a recombinant fusion protein 125I-rhTNT-IL2. J. Radioanalyt. Nucl. Chem., 273(1):3-8.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE